Table 3.

First line treatment proportions and associated confidence intervals

Line 1 treatment	Flatiron drug proportion ± confidence interval	McKesson drug proportion ± confidence interval	MarketScan drug proportion ± confidence interval	PharMetrics+ drug proportion ± confidence interval	Social media drug proportion ± confidence interval
Ipilimumab	24.8% ± 1.6%	45.2% ± 4.1%	16.7% ± 1.3%	34.9% ± 3.4%	42.2% ± 3.4%
Pembrolizumab	13.6% ± 1.3%	18.8% ± 3.2%	5.8% ± 0.8%	12.5% ± 2.4%	11.3% ± 2.2%
Vemurafenib	10.2% ± 1.2%	1.3% ± 0.9%	5.4% ± 0.8%	5.1% ± 1.6%	13.3% ± 2.3%
Dabrafenib and Trametinib	9.7% ± 1.1%	2.1% ± 1.2%	4.3% ± 0.7%	6.2% ± 1.7%	5.5% ± 1.6%
Ipilimumab and Nivolumab	9.4% ± 1.1%	13.8% ± 2.9%	3.5% ± 0.6%	9.7% ± 2.1%	6% ± 1.6%
Nivolumab	8.7% ± 1.1%	13.6% ± 2.8%	3.1% ± 0.6%	11.5% ± 2.3%	4.4% ± 1.4%

Note: Bold values indicate where social media estimates overlap with a database.